Peripheral artery disease
Peripheral artery disease, or PAD, is a narrowing of the blood vessels outside the heart, caused by atherosclerosis, a build-up of plaque in the artery walls. MedlinePlus says many people who have it have no symptoms, and that leg pain, numbness or heaviness on walking or climbing stairs is one sign. It says PAD can raise the risk of heart attack, stroke and transient ischemic attack, and names smoking as the main risk factor. NHLBI says roughly 1 in 4 of those with PAD have pain or weakness in the leg muscles that comes on with exercise and eases soon after rest.
Also called PAD · Peripheral arterial disease
- Condition
- In this atlas
Overview
Technical summary
MeSH D058729 is named Peripheral Arterial Disease; its scope note ties it to atherosclerosis, intermittent claudication and an ankle brachial index of 0.9 or less. MedlinePlus says the arteries involved supply blood to the arms and legs; NHLBI says its page focuses on lower extremity PAD, the most common type, and gives its symptom figure for that form.
Recognition
MedlinePlus says doctors diagnose PAD with a physical exam and heart and imaging tests.
Burden
No burden claims are published.
Claims and evidence
Context People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages
- Recipient
- Recipient not specified
- Population
- People with the condition each page covers. The pages give no age limits and no inclusion criteria.
- Care setting
- Not stated; patient information pages
- Geography
- Not stated; United States federal health agencies (NLM and NIH)
- Life stage
- Not stated on the pages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive pages)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
MedlinePlus says peripheral arterial disease is a narrowing of the blood vessels outside the heart that is caused by atherosclerosis, and that many people who have it have no symptoms. It says the disease can raise the risk of heart attack, stroke and transient ischemic attack. NHLBI says roughly 1 in 4 of those with PAD have pain or weakness in the leg muscles that comes on with exercise, for example walking, and eases soon after rest.
Applies to Recipient not specified People with deep vein thrombosis, pulmonary embolism, peripheral artery disease or pulmonary hypertension, as described in MedlinePlus and NHLBI patient pages
- Certainty method
- Not assessed
- Limitations
- Patient-education pages from US government sources. They give no study, no size of risk and no population, and they do not say how often any of this happens. The 1 in 4 figure is NHLBI's statement about symptoms of the lower-extremity form and the page gives no source for it.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
Supports Peripheral Arterial Disease (MedlinePlus health topic)
- Locator
- Summary, paragraph 1, sentence 1
- How it applies
- MedlinePlus: a narrowing of blood vessels outside the heart.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
9245c04c172ffec7f8064a2f9d88ed25f60372558c1c5e391ae80ec3d820cfd0- Reuse basis
- MedlinePlus says its summaries on health topic pages are in the public domain and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Peripheral Arterial Disease (MedlinePlus health topic)
- Locator
- Summary, paragraph 1, sentence 2
- How it applies
- MedlinePlus: the cause is atherosclerosis.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
9245c04c172ffec7f8064a2f9d88ed25f60372558c1c5e391ae80ec3d820cfd0- Reuse basis
- MedlinePlus says its summaries on health topic pages are in the public domain and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Peripheral Arterial Disease (MedlinePlus health topic)
- Locator
- Summary, paragraph 3, sentence 1
- How it applies
- MedlinePlus: many people have no symptoms.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
9245c04c172ffec7f8064a2f9d88ed25f60372558c1c5e391ae80ec3d820cfd0- Reuse basis
- MedlinePlus says its summaries on health topic pages are in the public domain and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Peripheral Arterial Disease (MedlinePlus health topic)
- Locator
- Summary, paragraph 4, sentence 1
- How it applies
- MedlinePlus: raised risk of heart attack, stroke and transient ischemic attack.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
9245c04c172ffec7f8064a2f9d88ed25f60372558c1c5e391ae80ec3d820cfd0- Reuse basis
- MedlinePlus says its summaries on health topic pages are in the public domain and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Peripheral Artery Disease: What Is Peripheral Artery Disease? (NHLBI)
- Locator
- What Is Peripheral Artery Disease?, paragraph 2
- How it applies
- NHLBI: exercise-triggered muscle pain or weakness, about 1 in 4. Last updated March 24, 2022 according to the page.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
bf2fb888c1fbaa445241f4b6e12467cc988bc8cf19d429d6b01dc22d49533c21- Reuse basis
- NHLBI is part of the U.S. National Institutes of Health. The pages carry third-party material, such as animations credited to Nucleus Medical Media, that this atlas does not use. NHLBI's own reuse terms were not read, so public text is cite_only until they are read; the rule can then change to quote. Hash only; the page is not committed.
-
Background MeSH scope note for descriptor D058729 (Peripheral Arterial Disease)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note for peripheral arterial disease.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
29cfbd052bc0c4ca51a3b75bf2d752ad3082b3495e2f6015f896d8d64c92b202- Reuse basis
- The NLM web policies page (fetched 2026-10-30, sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Clopidogrel
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Ankle-brachial index
Applies to Recipient not specified People who may have peripheral artery disease (MeSH scope note and two reviews)
Population, setting and follow-up
- People who may have peripheral artery disease or chronic limb-threatening ischemia, as the MeSH scope note and the reviews describe them. The automated-measurement review also discusses people with no symptoms; its device comparisons are not used.
- Primary care and vascular clinics, as the narrative review describes where the test can be done.
- Not stated for the reviews as a whole.
- Adults are implied but not stated. This record makes no statement about pregnancy, newborns or children.
- Gestational age Not reported
- Postnatal age Not reported
MeSH describes the ankle-brachial index as a comparison of the blood pressure between the brachial artery and the posterior tibial artery and as a predictor of peripheral arterial disease. A 2021 narrative review (Journal of Clinical Medicine) says it is often used for initial diagnosis of peripheral artery disease because it is non-invasive and less expensive and more accessible than imaging studies, says it is calculated by dividing systolic blood pressure at the ankle by systolic blood pressure at the arm, and says that, according to several studies, the test is often under-utilized or performed incorrectly in general practice. A 2023 review of chronic limb-threatening ischemia says its diagnosis needs pain associated with at least one abnormal hemodynamic parameter, such as the ankle brachial index.Limitations. A vocabulary scope note and two narrative reviews, with no study data of the atlas's own. The reviews give cut-off values, measurement methods and automated device findings, which are not repeated; the atlas gives no rule for reading a result. The underuse statement cites other studies.
-
Claim, not a settled fact Evaluated for this: Revascularization for peripheral artery disease (angioplasty, stenting, bypass)
Applies to Recipient not specified People with peripheral artery disease, including limb-threatening disease (MeSH scope note and three reviews)
Population, setting and follow-up
- People with peripheral artery disease considered for treatment of blocked leg arteries, as the MeSH scope note and the reviews describe them. One review is about chronic limb-threatening ischemia and another about disease below the groin (infrainguinal); neither is a single study population.
- Vascular surgery and endovascular treatment, as the reviews describe them.
- Not stated for the reviews as a whole.
- Adults are implied but not stated. This record makes no statement about pregnancy, newborns or children.
- Gestational age Not reported
- Postnatal age Not reported
MeSH describes endovascular procedures as minimally invasive procedures performed within the blood vessels. A 2025 systematic review (Journal of Clinical Medicine) calls bypass surgery and endovascular treatment the mainstream treatments for peripheral artery disease and says the choice of treatment varies and the best approach has been a subject of ongoing controversy; it also says guidelines widely recommend endovascular therapy for infrainguinal disease despite a lack of adequately powered data. A 2020 review (F1000Research) describes percutaneous transluminal angioplasty as one of the mainstays of endovascular therapy and says stents have evolved to include bare metal, covered and drug-eluting types. A 2023 review of chronic limb-threatening ischemia says there is still a lack of consensus on the best treatment strategy and that not all patients are suitable for revascularization.Limitations. Reviews that describe approaches and their debate. Pooled effect estimates, trial results, device results and each review's own conclusion about which approach to prefer are not repeated and not assessed, and the atlas makes no recommendation. The sources do not define bypass surgery beyond naming it, and they cover different parts of the leg arteries.
-
Claim, not a settled fact Evaluated for this: Supervised exercise therapy
Applies to Recipient not specified People with symptomatic peripheral artery disease (two reviews and a MeSH scope note)
Population, setting and follow-up
- People with symptomatic peripheral artery disease, mainly those with intermittent claudication (calf pain on walking), as the two reviews describe them. The 2015 systematic review pooled randomised trials; its results are not used.
- Supervised exercise programs, home-based programs and hospital or specialized-center programs, as the reviews describe them.
- Not stated for the reviews as a whole.
- Adults are implied but not stated. This record makes no statement about pregnancy, newborns or children.
- Gestational age Not reported
- Postnatal age Not reported
MeSH describes exercise therapy as a regimen or plan of physical activities designed and prescribed for specific therapeutic goals. A 2015 systematic review (Surgery Research and Practice) describes supervised exercise training as a prescribed, evidence based exercise program performed under the direct observation of a trained practitioner, says it is well established as an initial noninvasive option in peripheral artery disease, says study results suggest exercise is a complication-free treatment, and says it remains a greatly underutilized resource because of limited patient access. A 2023 narrative review (Journal of Clinical Medicine) says supervised exercise therapy has been shown to improve maximal oxygen consumption and to increase walking distance without calf pain, and that it has a poor adherence rate because of the long duration of hospitalization and a reduced number of specialized medical centers.Limitations. Two reviews and a vocabulary note, with no study data of the atlas's own. The introductions' statements cite other studies. Walking distances, trial comparisons, program content, intensity and schedule are not repeated, and the atlas gives no exercise prescription.
-
Claim, not a settled fact Evaluated for this: Vascular ultrasound (carotid and venous duplex)
Applies to Recipient not specified People who may have a blood flow condition (MedlinePlus test page and MeSH scope note)
Population, setting and follow-up
- People who have symptoms of abnormal blood flow or a condition that affects blood flow, as the MedlinePlus page describes them. This record uses only the statements about the arms, legs, neck and brain.
- A test done by a trained sonographer, as the page describes; the page also lists preparation and what happens during the test, which are not used.
- Not stated. The source does not name a country.
- Not restricted by the page, which also covers blood flow to the fetus in pregnancy. This record makes no statement about pregnancy or the fetus, newborns or children.
- Gestational age Not reported
- Postnatal age Not reported
MedlinePlus says a Doppler ultrasound is a type of ultrasound imaging test that uses sound waves to show how well blood flows through blood vessels, lists vascular ultrasound as another name, and describes duplex Doppler as using standard ultrasound to take images showing blood flow. It says a Doppler ultrasound of the arms and legs can help diagnose conditions that reduce blood flow, including deep vein thrombosis, peripheral arterial disease and varicose veins, and that one of the neck and brain can help look for conditions that affect blood flow to the brain, including carotid artery disease. MeSH describes duplex Doppler ultrasonography as applying the Doppler effect combined with real-time imaging, with the ability to estimate the velocity of flow.Limitations. General patient information and a vocabulary note, not a diagnostic rule. The page gives no accuracy figures or study data. Its statements on the heart, abdomen, transplanted organs and the fetus, its preparation and its results are not repeated; this record makes no statement about pregnancy.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 255
Record details
- Record id
cardio:peripheral-artery-disease- Content hash
18d6526ae49ef62ada6fa6ea980f58b88ca4d27f2673e5b56c976dedff4df09d